Genelux Corporation

NASDAQ:GNLX

Biotechnology

Healthcare
$2.24 +2.63%

+$0.08 today

Market cap
$107.66M
Beta
0.55
P/E (TTM)
-3.0
EPS (TTM)
-$0.98
52W Low $2.29High $8.54

Volume 0.80M

Average 0.19M

GNLX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Genelux CorporationNASDAQ: GNLX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $5.24M rose 11.6% year over year, ahead of the +3.6% change in trailing-twelve-month research & development. Sequentially, it fell 7.3% from the prior quarter. Over 3 fiscal years it compounded at +29.8% a year.

Context

  • Research & development amounted to 248137.5% of revenue in FY2025, up 10662.5 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +11.6% holds above the trailing-twelve-month pace of +3.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.24M-7.3% QoQ
Last fiscal yearDec 2025
$19.85M+4.5% YoY
LTMMar 2026
$20.4M+3.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.6%——
1 year+4.5%——
3-year CAGR+29.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
19.85M USD
Year-over-year change
+4.5%
4-year CAGR
+33.1%

Research & Development vs competitors

How GNLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3.6% is the 5th highest of 10, against a peer median of -11.7%.
  • Research & development amounts to 254962.5% of revenue for GNLX, versus a peer median of 3625.8%.
GNLX Competitors
Research & Development for GNLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$151.83M USD-11.7%-0.1%489780.6%
CLLSCellectis S.A.LTM Mar 2026$94.68M USD+5.0%-1.4%139.0%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$62.33M USD-17.5%+9.1%—
SLNSilence Therapeutics plcLTM Mar 2026$61.84M USD—+24.0%6710.8%
ACIUAC Immune S.A.LTM Mar 2026CHF 52.18M CHF-17.6%-2.2%1409.6%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$49.38M USD+11.3%+45.0%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$36.32M USD+88.9%+13.6%—
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$35.87M USD+29.3%+13.9%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$20.65M USD-58.3%-18.4%—
GNLXGenelux CorporationLTM Mar 2026$20.4M USD+3.6%+29.8%254962.5%
MREOMereo BioPharma Group plcLTM Mar 2026$18.13M USD-12.8%-16.7%3625.8%
Peer median (excluding GNLX) —-11.7%+4.5%3625.8%

Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue011.07M170K8K8K
Cost of Revenue895K968K1.02M903K574K
Gross Profit(895K)10.1M(848K)(895K)(566K)
Gross Margin—91.3%-498.8%-11187.5%-7075.0%
Research & Development6.32M9.08M12.77M19M19.85M
Selling, General & Admin8.29M5M11.57M12.71M13.37M
Operating Expenses13.72M13.11M23.32M30.8M32.65M
Depreciation & Amortization895K968K1.02M903K574K
EBITDA(13.67M)(1.73M)(26.46M)(28.97M)(31.57M)
EBITDA Margin—-15.6%-15562.9%-362075.0%-394637.5%
Operating Income(14.61M)(3.01M)(24.17M)(31.7M)(33.21M)
Operating Margin—-27.2%-14214.7%-396200.0%-415175.0%
Interest Income00244K1.46M1.07M
Interest Expense1.82M1.41M3.97M00
Other Income / Expenses(1.77M)(1.09M)(4.13M)1.83M1.07M
Income Before Tax(16.38M)(4.11M)(28.3M)(29.87M)(32.15M)
Pre-Tax Margin—-37.1%-16645.3%-373362.5%-401812.5%
Income Tax Expense01.1M000
Net Income(17.8M)(5.21M)(28.3M)(29.87M)(32.15M)
Net Margin—-47.0%-16645.3%-373362.5%-401812.5%
EPS (Basic)(0.69)(0.21)(1.16)(0.95)(0.86)
EPS (Diluted)(0.69)(0.21)(1.16)(0.95)(0.86)
Weighted Avg Shares23.62M24.55M24.43M31.45M37.18M
Weighted Avg Shares (Diluted)23.62M24.55M24.43M31.45M37.18M

Genelux Corporation

NASDAQ:GNLX

Intrinsic Alpha fair value

Locked

Current Price

$2.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.